nav-left cat-right

Analyzing the Winners and Losers in the Growth of Non-oral Patient Self-medication

Success of Delivery Device Developers in Solving Formulation Limitations a Key Factor according to Greystone Research Associates

(Amherst, NH) – As patients live longer and the prevalence and incidence of chronic ailments increase across the general population, drug developers and their delivery device partners are adapting to address what will become a significant market opportunity. Chronic conditions require drug administration over long periods of time, placing a greater emphasis on self-administration. With the shift away from caregiver interaction, drug safety and compliance/adherence become prominent concerns. These concerns, which are not new, are becoming magnified as the number of powerful new drugs reaching the market increases. For healthcare managers and public health officials, one way to address these issues is less frequent dosing.

While sustained release tablets and capsules continue to evolve, there are limitations to this approach to the dosing issue, and these limits have essentially been reached. This reality, and the fact that biological drugs cannot be delivered orally, have resulted in an accelerating interest in alternative modes of administration (MoA), a group that includes injection, inhalation and transdermal administration. Our analysis concludes that recent growth has been uneven across non-oral delivery segments, and that future prospects will be determined to a large degree by the ability of drug and device developers to address formulation and patient issues across the new drug landscape.

The leading beneficiary of current drug development pipelines and the move toward self-administration is the injectable segment. The transition of injectable drug packaging from vials to sophisticated and customized injection devices is accelerating at a time when caregiver and patient expectations continue to evolve. The result is an emerging set of de facto requirements for drug developers that often dictates the device strategy for a particular parental drug. This trend is strongly aligned within and around specific drug classes and is accelerating with each new injectable that reaches the market.

Oral inhalation appeared to be on track to be a significant factor in the shift to self-administered systemic drugs. But the effects of the withdrawal of Exubera from the market continue to impact this segment. With a few notable exceptions, the majority of product development and new drug launches in this MoA segment continue to be for upper respiratory conditions that include asthma and COPD.

Transdermal drug patches offer the advantages of ease of use, painlessness, disposability, control of drug delivery and avoidance of first-pass metabolism by the liver. Advances in synthetic materials and patch design have led to patches that are more esthetically acceptable and that are capable of delivering sustained dosing of active compounds for several days in a smaller package. The use of patches provides therapy with a single application that is more beneficial than the use of other dosage forms that need more frequent administration. It provides the opportunity for rapid discontinuation of the source of medication and it can be quickly applied to unconscious, comatose or non-responsive patients.

The global drug self-administration market is detailed in a new and comprehensive report researched and written by Greystone Research Associates. Drug Self-administration Markets to 2022 analyzes the global market for drug designed to be administered by the patient. The report examines drug self-administration by therapeutic market, method of delivery and competitor, and analyzes demand drivers, development factors, and market considerations. Strategic and economic factors and profiles of market sector participants are also provided.

More information is available at

About Greystone

Greystone Research Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

Source: Greystone Research Associates